1469 studies found for:    alzheimer disease
Show Display Options
Rank Status Study
21 Completed
Has Results
Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline
Condition: Alzheimer Disease
Interventions: Drug: Rivastigmine 5 cm^2;   Drug: Rivastigmine 10 cm^2;   Drug: Rivastigmine 15 cm^2;   Drug: Placebo to 15 cm^2 patch;   Drug: Placebo to 10 cm^2 patch
22 Completed Ecological Assessment of Apathy in Alzheimer's Disease and in Control Subjects: Video Recognition and Actigraphy
Condition: Alzheimer Disease
Intervention: Other: observational
23 Completed
Has Results
Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Drug: Rivastigmine 5 and 10 cm^2 patch
24 Recruiting Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease
Condition: Alzheimer Disease
Intervention: Drug: AADvac1
25 Completed
Has Results
A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Interferon beta-1a;   Drug: Placebo
26 Recruiting Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo
Condition: Alzheimer's Disease
Interventions: Drug: Solanezumab;   Drug: Placebo
27 Active, not recruiting Resveratrol for Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Resveratrol;   Drug: Placebo
28 Recruiting A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: BAN2401 2.5 mg /kg;   Drug: BAN2401 5 mg /kg;   Drug: BAN2401 10 mg /kg;   Drug: Placebo
29 Completed Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: PF-04360365 0.1 mg/kg;   Biological: PF-04360365 0.5 mg/kg;   Biological: PF-04360365 1 mg/kg;   Drug: Placebo;   Biological: PF-04360365 3 mg/kg;   Biological: PF-04360365 8.5 mg/kg
30 Active, not recruiting Alzheimer's Disease Neuroimaging Initiative 2
Conditions: Mild Cognitive Impairment (MCI);   Alzheimer's Disease
31 Completed Life From Vision in Alzheimer Disease
Conditions: Alzheimer Disease;   Cataract
Intervention: Behavioral: Questionaries
32 Completed Improved Diagnosis of Alzheimer's Disease Using the Synchronous Neural Interaction™ Test
Condition: Alzheimer's Disease
33 Unknown  Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: Bryostatin for Injection;   Drug: Placebo
34 Completed Effect of LY450139 on the Long Term Progression of Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Drug: LY450139;   Drug: placebo
35 Completed Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)
Condition: Alzheimer's Disease
Interventions: Drug: Donepezil;   Drug: AZD3480
36 Completed Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease
Conditions: Alzheimer's Disease;   Central Nervous System Diseases;   Cognition
Interventions: Drug: EVP-6124;   Drug: Placebo
37 Unknown  Clinical Trial of Donepezil Between the Patients With Alzheimer's Disease and Mixed Dementia
Conditions: Alzheimer's Disease;   Dementia
Intervention: Drug: donepezil
38 Completed Assessment of Sleep Disturbance in Alzheimer Disease
Condition: Alzheimer Disease
Intervention: Other: Analysis of sleep disturbance
39 Recruiting Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Conditions: Alzheimers Disease;   Dementia;   Alzheimers Disease, Familial
Interventions: Drug: Gantenerumab;   Drug: Solanezumab;   Drug: Matching Placebo (Gantenerumab);   Drug: Matching Placebo (Solanezumab)
40 Completed A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED)
Condition: Alzheimer's Disease
Interventions: Other: MRI;   Other: FDG-PET

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years